NL-OMON50127已完成不适用
Single center, open-label, non-randomized, non-placebo-controlled study to investigate the pharmacokinetics, metabolic disposition and mass balance after single administration of 25 mg [14C]BAY 2433334 (oral solution) in healthy male participants. - Human Mass Balance Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer AG
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy white male
- •Between 18 and 55 years of age.
- •BMI is between 18 and 29.9 kilograms/meter2
排除标准
- •1. A history of relevant diseases of vital organs, of the central nervous
- •system or other organs.
- •2. Medical disorder, condition or history of such that would impair the
- •participant's ability to participate or complete this study in the opinion of
- •the investigator.
- •3. Incompletely cured pre-existing diseases for which it can be assumed that
- •the absorption, distribution, metabolism, elimination and effects of the study
- •intervention will not be normal.
- •4. Known hypersensitivity to the study interventions (active substance or
- •excipients of the preparation).
- •5. Known severe allergies e.g. allergies to more than 3 allergens, allergies
- •affecting the lower respiratory tract - allergic asthma, allergies requiring
- •therapy with corticosteroids, urticaria or significant non-allergic drug
研究者
相似试验
已完成
不适用
Single center, open-label, non-randomized, non-placebo-controlled study to investigate the metabolism, excretion pattern, mass balance, safety, tolerability and pharmacokinetics after single administration of 200 mg [14C]rogaratinib (oral solution) in healthy male subjectsNL-OMON46572Bayer AG6
已完成
不适用
Single center, open-label, non-randomized, non-placebo-controlled study to investigate the pharmacokinetics, metabolic disposition and mass balance after single administration of 5 mg [14C]BAY 1021189 (oral solution) in healthy male subjectsheart failureCardiovascular diseases10019280NL-OMON40889Bayer6
已完成
不适用
Single center, open label, non-randomized, non-placebo controlled study to investigate the pharmacokinetics, metabolic disposition, and mass balance after single administration of 20 mg [14C]neladenoson bialanate (oral solution) in healthy male subjects.10019280heart failureNL-OMON44620Bayer AG6
尚未招募
Unknown
Exploring Safety and Effectiveness of HI-GRIP VC Bandage for Chronic Leg UlcersCTRI/2024/07/070977Outcare Medical Device Pvt Ltd
进行中（未招募）
1 期
A single center, open-label, non-randomized, uncontrolled, multiple-dose study of the efficacy and safety of Metazym (recombinant human arylsulfatase A or rhASA) for the treatment of MLD patients with high residual level of voluntary functioEUCTR2007-007165-20-DKShire Pharmaceuticals Ireland Limited6